COVID Vaccine Sputnik V Manufacturer Hits Upper Circuit, Secures Rs 127 Crore Order from UNICEF – FIIs and DIIs Increase Stake
The company’s shares have delivered an impressive return of over 220 per cent in the past year.
Incorporated in 1984, Panacea Biotec Ltd is a Small-Cap research-based biotechnology company based in India. The company specializes in research, development, manufacturing, and marketing of branded vaccines, pharmaceutical formulations, nutraceuticals, and food and nutrition products for both domestic and international markets. Its operations are divided into two main segments: vaccines and formulations. Notably, Panacea Biotec has expertise in developing fully liquid combination vaccines that can be stored at 2-8°C.
In 2021, Panacea Biotec Ltd signed an agreement with the Russian Direct Investment Fund (RDIF) to manufacture 100 million doses per year of Sputnik V, the world’s first registered COVID-19 vaccine.
The company has been granted a Letter of Award by UNICEF for the supply of 115 million doses of its bivalent oral polio vaccine (bOPV) during the calendar year 2025. The contract, valued at approximately USD 14.95 million (Rs 127 crore), is contingent on signing the requisite amendment to the existing Long-Term Arrangement (LTA). This development underscores Panacea Biotec's continued contribution to global immunization initiatives, aligning with UNICEF’s efforts to combat polio worldwide.
DSIJ's ‘Penny Pick’ service provides research-backed penny stock recommendations below Rs. 100. If this interests you, do download the service details here.
Read Military Bulletproof Jackets and Helmets Manufacturing Stock Hits Upper Circuit Today – Q2 FY25 Profits Surged by 133 Per cent YoY!
At the start of the day's trading session, shares of Panacea Biotec Ltd opened at Rs 456.25 per share, compared to the previous day's closing figure of Rs 434.55 per share on the BSE. Currently, the shares are at Rs 449 per share. The stock has rallied 5 per cent today and hit the upper circuit, reflecting strong demand in the market. The company's current market capitalization stands at Rs 2,750 crore. Additionally, the company’s shares have delivered a 220 per cent multibagger return in just 1 month.
As per the Quarterly Results, in the Q2 FY25, Panacea Biotec Ltd recorded a revenue of Rs 147.35 crore compared to Rs 143.02 crore. The operating profit stood at Rs 7 crore. The company reported a net profit of Rs 4.71 crore compared to a loss of Rs 8.29 crore
According to the company's shareholding pattern, the promoters hold a significant 72.87 per cent stake. Public investors own 25.60 per cent of the shares, while Foreign Institutional Investors (FIIs) hold 0.37 per cent and Domestic Institutional Investors (DIIs) own 1.16 per cent.
Investors must keep this small-cap stock on their radar.
Disclaimer: The article is for informational purposes only and not investment advice.